Luis Reyes has more than 35 years of nuclear experience. He served in various Nuclear Regulatory Commission (NRC) senior management positions, and the NRC consistently received the highest rating on its Government Performance Assessment review during his tenure. Reyes also served as executive-on-loan to the U.S. Department of Energy (DOE) to conduct a nuclear safety review at the DOE Assistant Secretary’s request. He was an expert consultant to the International Atomic Energy Agency (IAEA) in the areas of operations experience, new nuclear plant construction, and regulatory organizations. On behalf of the IAEA, Reyes led a team of international experts in the review of a European country’s regulatory organization. He is currently owner of Luis Reyes Consulting LLC.
Reyes’ numerous honors and awards include the Presidential Distinguished Rank award and the Presidential Meritorious Rank award, which he was awarded three times. These awards are distributed by the President of the United States to a small group of career senior executives and senior career employees. Reyes earned a Bachelor of Science in electrical engineering and a Master of Science in nuclear engineering from the University of Puerto Rico-Mayaguez. He also attended the Federal Executive Institute at the Harvard University Kennedy School of Government.
Dr. James Welsh
James Welsh, MS, MD, FACRO, is a board-certified radiation oncologist and neuro-oncologist. Dr. Welsh obtained his master’s degree in molecular biophysics and biochemistry from Yale University and his M.D. from the State University of New York at Stony Brook. He completed his residency training at The Johns Hopkins Hospital in Baltimore, Maryland and stayed on the Johns Hopkins faculty as an Assistant Professor of Oncology until 2001. Subsequently, Dr. Welsh completed a fellowship at the University of Wisconsin investigating helical TomoTherapy, a newly developed form of image-guided, intensity-modulated radiotherapy technology. He joined the faculty at the University of Wisconsin and became Clinical Professor of Human Oncology and Medical Physics. From there, Dr. Welsh served brief stints as Professor of Neurosurgery and Radiology at the Louisiana State University School of Medicine–Shreveport and as a radiation oncologist at Willis-Knighton Hospital. He then returned to the Midwest as the fast neutron therapy physician at the Northern Illinois University Institute for Neutron Therapy at Fermilab.
Dr. Welsh is currently Professor, Medical Director, and Director of Clinical & Translational Research in the Department of Radiation Oncology at the Stritch School of Medicine at Loyola University-Chicago and Chief of Radiation Oncology at the Edward Hines Jr. VA Hospital. He is also Chairman of the Board for the American College of Radiation Oncology, sits on the editorial boards for several scientific and medical journals, and serves on the Advisory Committee on the Medical Uses of Isotopes, which advises the NRC on medical issues.
Michael Matte is CFO for Forward Industries Inc. He has extensive experience as a CFO with public and private companies, including Aspen Group, Meet me Inc. (formerly Quepasa Corporation), Cyberguard Corporation, Amerijet International, Intime Systems International, Inc., and TORWEST, Inc. He also served as a senior audit manager for Price Waterhouse from 1981 to 1992. Matte has significant experience in rapidly growing businesses and his industry experience includes technology, software development, distribution, transportation, and medical diagnostic equipment.
Dr. Pedro Serrano-Ojeda
Dr. Pedro Serrano-Ojeda, M.D., is a certified radiation oncologist who founded Caribbean Radiation Oncology Center in Puerto Rico in 2007. He expanded the company in 2015, opening a second location in Doral, Florida. The facility is one of the first in Florida to feature the TomoTherapy HAD unit – the latest TomoTherapy Hi-Art Treatment System and the most integrated and advanced system for comprehensive cancer treatment that is available today.
Dr. Serrano-Ojeda received his medical degree from the Ponce School of Medicine & Health Sciences. During his residency at the Medical College of Wisconsin, he studied under the guidance of prominent medical professionals such as Dr. Frank Wilson, the protégé of the legendary radiation oncologist Dr. Juan Del Regato. In 2009, quality control data for Caribbean Radiation Oncology Center’s first 264 patients was published in the journal, Medical Physics. It was the largest study at the time.
Dr. Serrano-Ojeda has spoken at conferences throughout the U.S. and Latin America on behalf of TomoTherapy and Accuray, the manufacturer of the TomoTherapy technology, to teach techniques and offer insight on his experience with the machines.
Ian Turner is a successful CEO with prodigious international experience in high technology industries, specializing in the leadership of global organizations undergoing change. He has a record of corporate success in radiopharmaceuticals, nuclear industries, life sciences, and medical devices. Turner is currently CEO/Executive Consultant for Turner Group.
Most recently, Turner served as CEO and President at Siemens where he was responsible for the global PETNET and Cyclotron businesses. PETNET operates the largest PET radiopharmaceutical network in the world with over 55 radiopharmacies in seven countries.
Previously, Turner was responsible for the radiopharmaceuticals business of the Australian Nuclear Science and Technology Organisation (ANSTO) in Australia, which is home to INVAP’s OPAL nuclear reactor. He successfully created and led ANSTO’s initiative to be the first international commercial supplier of Molybdenum-99 derived from low enriched uranium. He also served on the Organisation for Economic Co-operation and Development High-level Group on the Security of Supply of Medical Radioisotopes.
Turner has master’s and bachelor’s degrees in electronic engineering from RMIT University in Melbourne, Australia and has a Company Directors Diploma from the Australian Institute of Company Directors. He is a sought-after public speaker and global authority on PET and SPECT radiopharmaceuticals. Turner has served on various boards in different countries and consults for private equity firms. He is well published and has a number of patents.